Financials in USD. Standardized financial statements.
A compact view of how Pear Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue? | $12.69M | $4.21M | $9.38M | $32.56M |
| Revenue Growth? | +201.7% | -55.2% | -71.2% | 0.0% |
| Cost of Revenue? | $8.18M | $5.23M | $1.72M | $998,000 |
| Gross Profit? | $4.51M | -$1.02M | $7.67M | $31.56M |
| Gross Margin? | +35.5% | -24.4% | +81.7% | +96.9% |
| Operating Expenses? | $127.86M | $104.66M | $84.31M | $63.17M |
| Operating Income? | -$123.35M | -$105.69M | -$76.64M | -$31.60M |
| EBITDA? | -$169.40M | -$152.43M | -$75.22M | -$51.70M |
| Income Before Tax | -$75.49M | -$65.14M | -$97.02M | -$9.33M |
| Income Tax Expense | -$51.75M | -$44.85M | $3.56M | -$21.73M |
| Net Income? | -$23.74M | -$20.29M | -$100.58M | $12.39M |
| EPS? | $-0.17 | $-0.18 | $-0.73 | $0.09 |
| Diluted EPS? | $-0.17 | $-0.18 | $-0.73 | $0.09 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality